Biotechnology

Aptose Biosciences

Aptose Biosciences Reports New Progress in AML Treatment

Aptose Biosciences Advances Tuspetinib Triple Therapy Clinical Trial

Aptose Delays Interest Payment Amid Financial Challenges

Aptose Biosciences and Haminpharm Reach $8.5 Million Loan Agreement

Aptose Biosciences Displays Clinical Trial Data for AML Triple-Therapy at EHA

Aptose Bioscience Administers Tuspetinib to First Patient

Aptose Bioscience Releases Restated Financial Results

Aptose Biosciences to Report on Triple Therapy Clinical Data at EHA 2025

Aptose Bioscience Reports Q1 2025 Net Loss Down

Aptose reports positive results for AML study

Aptose Developing Tri-drug Frontline Therapy for AML

Aptose Biosciences released FY2024 annual earnings on March 28 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -36.3815 USD (forecast -42.845 USD)

Aptose Biosciences released FY2024 Q4 earnings on March 28 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -1.3373 USD (forecast -6.775 USD)

Aptose Biosciences Reports Financial Performance for 2024, Highlights Progress in Acute Myeloid Leukemia Therapy

Aptose Biosciences Expects a Loss of $10.50 per Share in the 2024 Quarter Report, Analysts Maintain 'Buy' Rating

Aptose Biotech Receives Approval to Increase Tuspetinib Dose in TUSCANY Trial

Aptose Biotech's TUSCANY Trial Shows Significant Efficacy in Newly Diagnosed Acute Myeloid Leukemia Patients

Aptose Biosciences released FY2024 9 Months Earnings on November 8, 2024 (EST) with actual revenue of 0 USD and EPS of -46.2443 USD

Aptose Biosciences released FY2024 Q3 earnings on November 8 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -11.2386 USD (forecast -19.2 USD)

Aptose Biosciences released FY2024 Semi-Annual Earnings on August 8 (EST) with actual revenue of 0 USD and EPS of -33.9106 USD

Processa Pharmaceuticals

cbdMD

Agape ATP

VYNE Therapeutics

Inspirato

Mega Fortune

Globavend

Andersen

Medline Inc.

DBV Tech

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap